Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Among the key challenges in Alzheimer's disease drug development is the timely completion of clinical trials. Unfortunately, clinical trials often suffer from slow or insufficient enrollment. Successful clinical trial recruitment describes a balance between expeditiously achieving full enrollment and ensuring an appropriate study sample. Investigators face a number of challenges to the successful negotiation of this balance. The failure to address these challenges means that drug development may take more time and money and that trial results may not adequately represent drug efficacy or may not be applicable beyond the study. We review the challenges to recruitment and retention in Alzheimer's disease clinical trials and present a framework to address them.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168 · cited 2×
“Th e majority of all AD patients are older than 75 years [43], increasing the likelihood of exclusion for reasons such as comorbidities or prohibited medications.”
BackgroundMemantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043 · cited 2×
“Th e initial trial of memantine in moderate-to-severe AD (MMSE 3 to 14) enrolled 252 subjects at 32 US sites over the course of 9 months [12] and demonstrated a signifi cant diff erence from placebo on the primary effi cacy outcomes.”
BackgroundMixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844 · cited 1×
“In the very few occasions in which two active treatments were tested against placebo [37, 38 ], we combined all active treatments in a single group.”
MethodInfluence of education and occupation on the incidence of Alzheimer's disease
Stern, Y. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370056032 · Cited by 1,434
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
Dementia and Alzheimer Disease Incidence: A Prospective Cohort Study
Kukull, W. A., Higdon, R., Bowen, J. D., McCormick, W. C., Teri, L., Schellenberg, G. D., van Belle, G., Jolley, L., & Larson, E. B. (2002) · Archives of Neurology · doi:10.1001/archneur.59.11.1737 · Cited by 806 · cited 1×
“Th e over-representation of highly educated participants is common among AD trial populations [14] and stands in stark contrast to epidemiologic studies, which consis tently demonstrate that less than 12 years of education is a signifi cant risk factor for AD [15,16].”
ResultA phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Cited by
Dysken, M. W., Sano, M., Asthana, S., Vertrees, J. E., Pallaki, M., Llorente, M., Love, S., Schellenberg, G. D., McCarten, J. R., Malphurs, J., et al. (2014) · JAMA · doi:10.1001/jama.2013.282834 · Cited by 628
Obstacles and opportunities in Alzheimer’s clinical trial recruitment
Watson, J. L., Ryan, L., Silverberg, N., Cahan, V., & Bernard, M. A. (2014) · Health Affairs · doi:10.1377/hlthaff.2013.1314 · Cited by 204
Activity-dependent neural plasticity from bench to bedside
Ganguly, K., & Poo, M.-M. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.028 · Cited by 202
Chandler, M. J., Parks, A. C., Marsiske, M., Rotblatt, L. J., & Smith, G. E. (2016) · Neuropsychology Review · doi:10.1007/s11065-016-9330-4 · Cited by 169
Indorewalla, K. K., O’Connor, M. K., Budson, A. E., Guess (DiTerlizzi), C., & Jackson, J. (2021) · Journal of Alzheimer’s Disease · doi:10.3233/jad-201081 · Cited by 93
“AD clinical trials have historically focused on recruiting spouses as study partners [2, 30, 58].”
BackgroundFleiner, T., Dauth, H., Gersie, M., Zijlstra, W., & Haussermann, P. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0289-z · Cited by 48
Rasmussen, I. D., Boayue, N. M., Mittner, M., Bystad, M., Grønli, O. K., Vangberg, T. R., Csifcsák, G., & Aslaksen, P. M. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-210378 · Cited by 42
Metadata
- Authors
- Grill, J. D., & Karlawish, J.
- Venue
- Alzheimer's Research & Therapy
- Published
- 2010
- Volume
- 2
- Issue
- 6
- Pages
- 34
- ISSN
- 1758-9193 (ISSN-L)
- OpenAlex
- W2157764095
- Cited by
- 198
- References
- 20
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.